If you have a diagnosis of Chronic Obstructive Pulmonary Disease (COPD) for 12 months or longer, and are currently taking Advair®, Symbicort®, or Seretide® (LABA/ICS) you may qualify to take part in a clinical research study. The purpose of this study is to investigate whether roflumilast may potentially reduce the frequency of exacerbation in people with severe Chronic Obstructive Pulmonary Disease (COPD), when used in addition to a fixed dose combination therapy (Advair® or Symbicort®).
To qualify patients must:
Be 40 years of age or older
Have a smoking history of greater than 20 pack years (Pack year = [#packs/per day smoked] x [years smoked])